psychiatrist

This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activity

FDA-Approved Medications to Treat Tardive Dyskinesia

Joseph P. McEvoy, MD

Published: December 17, 2019

Abstract

Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.

Overview

Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Learn more from Dr. Joseph McEvoy.
From the Series: Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia
To cite: McEvoy JP. FDA-Approved Medications to Treat Tardive Dyskinesia. J Clin Psychiatry 2020;81(1):NU18041BR3C.
To share: https://doi.org/10.4088/JCP.NU18041BR3C
© Copyright 2019 Physicians Postgraduate Press, Inc.

Target Audience

  • Psychiatrists
  • Neurologists
  • Nurse practitioners
  • Physician assistants

Learning Objectives

After completing this educational activity, you should be able to:

  • Select FDA-approved medication to treat TD symptoms, considering research on longer-term efficacy and safety

Support Statement

Supported by an educational grant from Neurocrine Biosciences, Inc.

Learning Objective

After completing this educational activity, you should be able to:

  • Select FDA-approved medication to treat TD symptoms, considering research on longer-term efficacy and safety.

Release, Review, and Expiration Dates

This brief report activity was published in November 2019 and is eligible for AMA PRA Category 1 Credit™ through November 30, 2021. The latest review of this material was September 2019.

Statement of Need and Purpose

Because some clinicians underestimate the risk of TD, especially with newer antipsychotics, they do not advise patients and caregivers of the risk of TD or educate them about early signs to watch for and report. A substantial proportion of patients with TD do not have a timely diagnosis. Clinicians may not recognize early TD symptoms, as mild cases may be more easily missed. Due to TD movements, patients may stop taking their treatments for mood disorders or schizophrenia. Clinicians may inaccurately rate how bothersome side effects are to patients. New medications for TD are available, and evidence-based treatment recommendations have been published. Recent research has explored longer-term safety and efficacy with newer medications. Clinicians need up-to-date guidance on the prevalence of TD, risk factors for TD, recognition of early signs and symptoms of TD, and assessment tools that will help them diagnose and monitor TD. They also need education about discussing TD risk and signs with patients and family members and should be aware of the burden of TD for patients and families. Up-to-date, evidence-based, expert guidance should be provided on using new medications to treat TD in patients with mood disorders and schizophrenia, including longer-term use. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on TD.

Disclosure of Off-Label Usage

Dr McEvoy has determined that, to the best of his knowledge, the following drugs are not approved by the US Food and Drug Administration for the treatment of tardive dyskinesia: lithium, botulinum toxin, amantadine, tetrabenazine, Ginkgo biloba, and clonazepam.

Review Process

The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.

Acknowledgment

This Brief Report is derived from the teleconference series “Early Recognition and Treatment of Tardive Dyskinesia in Patients with Mood Disorders and Schizophrenia,” which was held in April, May, and June 2019 and supported by an educational grant from Neurocrine Biosciences, Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.

Faculty Affiliation


Joseph P. McEvoy, MD
Medical College of Georgia, Augusta

Financial Disclosure

The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure is as follows:
Dr McEvoy has received grant/research support from Takeda, Alkermes, Boehringer Ingelheim, Teva, Neurocrine, and Otsuka; has received honoraria from Neurocrine; and is a member of the speaker/advisory boards for Merck, Neurocrine, and Alkermes.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

MOC Approval Statement

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, FDA-Approved Medications to Treat Tardive Dyskinesia has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity

Psychiatry and Neurology

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation

This CME activity is expired. For more CME activities, visit cme.psychiatrist.com.
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Tardive dyskinesia (TD), a condition characterized by involuntary movements of the face, torso, extremities, and sometimes the respiratory system, is usually observed in patie​nts after long-term treatment with antipsychotic agents or other agents that block dopamine receptors.1,2 Symptoms of TD are associated with reduced quality of life and psychosocial problems, such as social isolation and embarrassment,3,4 and can also contribute to medication nonadherence.5

 PATIENT PERSPECTIVES


Patient interview conducted by Joseph P. McEvoy, MD.

Over the years, many agents have been tested in the treatment of TD, including dopamine-depleting agents, dopamine agonists, noradrenergic agonists and antagonists, GABAergic drugs, lithium, calcium channel blockers, serotonergic drugs, vitamins, branched-chain amino acids, neuropeptides, cholinergic precursors and cholinesterase inhibitors, and botulinum toxin.6

The American Academy of Neurology (AAN) published evidence-based guidelines regarding TD in 2013, but few treatment options had sufficient data to support or refute their use.7 At the time, no treatments for TD had been approved by the US Food and Drug Administration (FDA). Recently, a review of new evidence was combined with the existing guideline evidence to provide updated treatment recommendations.8 This activity provides an overview of treatments for patients with TD based on the AAN’s recommendations.8 Treatments are categorized by various levels of evidence, with Level A being a recommended, effective treatment; Level B, probably effective; and Level C, possibly effective.

Off-Label Strategies

On rare occasions, usually if TD is mild and of recent onset, reductions in the dosing of dopamine receptor blocking agents and the prescription of agents such as amantadine may result in improvement in a small percentage of patients.8 However, reduction in antipsychotic dosing could destabilize patients.9

According to the treatment guideline, amantadine and tetrabenazine are agents with Level C evidence.8

Amantadine. Amantadine is a noncompetitive glutamate receptor antagonist. It is postulated to work by increasing presynaptic release of dopamine and blocking presynaptic dopamine reuptake.10 Two small placebo-controlled trials reported that amantadine, when combined with neuroleptics, reduced overall AIMS scores by an average of 15% and 22%.11

Tetrabenazine. Tetrabenazine is a vesicular monoamine transporter type 2 (VMAT2) inhibitor that depletes dopamine in the brain.12 It was approved by the FDA in 2008 for the treatment of chorea in Huntington’s disease.13

Studies11,14 suggest that tetrabenazine can reduce the severity of TD movements. However, the potential for adverse effects (eg, drowsiness, parkinsonism, akathisia, depression with suicidal ideation)11 and lack of large, long-term treatment trials14 have prevented its wide use.

Medication-induced TD is believed to result from hypersensitive dopamine D2 receptors,10 and the amount of dopamine in the synapse will determine how frequently these hypersensitive receptors are triggered, initiating involuntary movements. Tetrabenazine, however, is not specific for dopamine and also depletes presynaptic vesicles that collect and release serotonin, which puts patients at increased risk for depression and suicide. In addition to a black box warning for depression and suicide,12 tetrabenazine has active metabolites that act directly as dopamine receptor blocking agents capable of causing or worsening acute extrapyramidal side effects, such as slowness and stiffness, restlessness, dystonia, and tremor. Finally, tetrabenazine is also an agent with a short half-life, requiring gradual titration up to dosing of 3 times daily.12

Ginkgo biloba and clonazepam may occasionally be useful for TD.1 They have Level B evidence,8 but the risk-benefit profile is unfavorable.

Ginkgo biloba. A double-blind, randomized controlled trial comparing Ginkgo biloba extract and placebo in patients with schizophrenia and TD found that AIMS scores significantly decreased (P < .0001) in patients receiving ginkgo biloba versus those receiving placebo.7 However, clinicians must be aware that dietary supplements such as ginkgo biloba are not regulated by the FDA, which means there is no guarantee of strength, purity, or safety.15

Clonazepam. While certain benzodiazepines can cause TD, some may be beneficial in treating it.10 Clonazepam, a GABA-α agonist, has shown some effect in reducing involuntary movements in patients with TD.1

In a 12-week study, clonazepam reduced symptoms of TD (P < .001), but for patients who continued treatment up to 9 months of open study, the drug’s effect stopped after 5–8 months.7 Clinicians must be aware that clonazepam is a controlled substance with potential for abuse.16

FDA-Approved TD Treatments

Two treatments for TD have been approved by the FDA and have Level A evidence: valbenazine and deutetrabenazine (AV 1).17–21 Both agents are novel VMAT2 inhibitors and are believed to be better treatment options than off-label tetrabenazine due to tetrabenazine’s pharmacokinetic profile that requires higher, more frequent doses with greater potential for adverse effects.22 The new medications can be life changing for individuals with TD who continue to need antipsychotic treatment despite the side effects.

AV 1. Comparison of Approved Drug Treatments for Tardive Dyskinesia (0:16)

Based on Citrome 2018,17 Citrome 2017,18 and Citrome 2017,19 and package inserts for valbenazine20 and deutetrabenazine.21 Always check the full prescribing information for updates.
aNumber needed to treat is based on percentage of responders in Phase 3 acute studies with a 50% or greater reduction from baseline in the Abnormal Involuntary Movement Scale dyskinesia score.

 FAMILY PERSPECTIVES


Interview conducted by Joseph P. McEvoy, MD.

Valbenazine. Valbenazine is the purified parent product of one of the main tetrabenazine metabolites.22 The amino acid valine is linked by an ester bond to a metabolite of tetrabenazine.20 Valbenazine is slowly metabolized, allowing for once-daily dosing.

In a phase 2 study23 examining flexible doses of 25 to 75 mg/d of valbenazine, valbenazine proved superior to placebo in reducing AIMS dyskinesia scores (mean change of –2.6 vs –0.2, respectively; a decrease of 2 points is considered clinically meaningful24). A phase 3 study25 examined 40 mg/d and 80 mg/d of valbenazine versus placebo in patients with schizophrenia, schizoaffective disorder, or mood disorder (N = 205). The 80 mg/d dose produced a greater reduction in AIMS dyskinesia scores than the 40 mg/d dose (–3.2 vs –1.9) and placebo (–0.1).

An initial 40-mg/d dose and subsequent 80-mg/d dose is recommended for most patients; patients may be continued at 40 mg/d if metabolism is problematic.20 The most common adverse effect of valbenazine is somnolence,20 and it is also associated with fatigue, headache, gastrointestinal disturbance, and potentially prolonged QT interval. Studies have not detected differences in cardiovascular outcomes with valbenazine versus placebo.26 Psychiatric stability was maintained during 1 year of treatment, with few participants experiencing suicidal ideation despite the presence of a lifetime history of suicidality in up to 40%.27 Psychiatric stability was similar whether patients’ primary illness was a mood disorder or schizophrenia.28

Results from a 42-week extension study29 showed that reductions in mean AIMS score were maintained (AV 2). The mean changes in AIMS scores from baseline at week 48 were –3.0 with 40 mg/d and –4.8 with 80 mg/d. However, after the 4-week discontinuation and washout period, TD symptoms returned to baseline levels.28,30 Valbenazine suppresses the abnormal movements but does not reverse the underlying damage from excessive dopamine blockade; therefore, ongoing treatment is needed.

Valbenazine is metabolized through cytochromes CYP2D6 and CYP3A4, so to avoid drug interactions, clinicians must consider other agents patients are taking that are metabolized by these cytochromes.20

AV 2. Ongoing Suppression of Tardive Dyskinesia Symptoms With Valbenazine (0:29)

Adapted with permission from Factor et al.29
**P < .01 vs placebo.
***P < .001 vs placebo.
§P < .001 vs baseline.
Abbreviations: AIMS = Abnormal Involuntary Movement Scale; DBPC = double-blind, placebo-controlled period; SEM = standard error of the mean; VBZ = valbenazine; VE = valbenazine extension period.

Deutetrabenazine. The hydrogen atoms that are the initial targets in the metabolism of tetrabenazine are replaced by deuterium atoms in deutetrabenazine.19 Deuterium is a nonradioactive, stable isotope of hydrogen. Instead of having 1 proton nucleus circled by 1 electron like hydrogen does, deuterium has 1 electron and both 1 neutron and 1 proton in its nucleus, making it twice the molecular weight of hydrogen.31 The bonds between carbon and deuterium in deutetrabenazine are stronger than the bonds between carbon and hydrogen, which slows the metabolism of deutetrabenazine and allows reduction of peak-trough variation.30 Deutetrabenazine is taken twice daily with food.

A multicenter study32 examined a flexible dose of deutetrabenazine starting at 12 mg/d (6 mg twice daily) and titrated weekly by 6 mg/d, if required, versus placebo in 117 patients with moderate-to-severe TD. Over 12 weeks, AIMS scores decreased significantly in the deutetrabenazine group versus the placebo group (−3.0 vs −1.6; P = .019), and the drug was well tolerated.

A phase 3 fixed-dose study33 examining 12-mg, 24-mg, and 36-mg daily doses of deutetrabenazine, found that the 24-mg/d and 36-mg/d doses were superior to placebo in reducing AIMS dyskinesia scores (–3.2 in the 24 mg/d group, –3.3 in the 36 mg/d group, and –2.1 in the 12 mg/d group vs –1.4 in the placebo group).

A long-term open-label extension34 of the placebo-controlled trials followed patients through week 106. Improvements from baseline in AIMS scores were maintained through endpoint (AV 3).34

AV 3. Ongoing Suppression of Tardive Dyskinesia Symptoms With Deutetrabenazine (0:25)

Data from Fernandez et al.34
Abbreviation: AIMS = Abnormal Involuntary Movement Scale.

The rates of side effects were similar with all 3 doses of deutetrabenazine (44%–51%) as with placebo (47%).33 The 5 most common adverse reactions were somnolence, fatigue, insomnia, headache, and diarrhea.33 Deutetrabenazine has a black box warning that states that it can increase the risk for depression and suicidality in patients with Huntington’s disease.21 During long-term treatment in patients with TD, suicidal ideation was reported in 5% of patients (5%) and suicidal behavior in < 1%; the majority of those participants had a history of depression or suicidal behavior.34

Deutetrabenazine will compete with other drugs metabolized through cytochrome CYP2D6. In patients who have been tested and are known to be CYP2D6 slow metabolizers or in those with concomitant use of strong CYP2D6 inhibitors, deutetrabenazine doses greater than 18 mg twice daily are not recommended.21 Deutetrabenazine can slightly prolong the QT interval, so it should not be considered in patients with congenital long QT syndrome or with a history of cardiac arrhythmias. Deutetrabenazine should also be avoided or used with caution in patients with QT prolongation from other causes.21

Conclusion

Clinicians now have 2 FDA-approved agents to consider in the treatment of TD. Both valbenazine and deutetrabenazine are effective and tolerable agents. Neither is curative, but continuous treatment can successfully reduce TD symptoms. Clinicians should know the differences between the medications, such as administration, titration, and contraindications. Clinicians should make patients aware of any potential adverse effects. With these new options, clinicians may better help patients overcome the troubling effects of TD.

Clinical Points

  • Treat patients who have TD with evidence-based agents
  • Differentiate between the 2 FDA-approved agents for TD
  • Follow recommended administration, titration, and monitoring of medications for TD

Abbreviations

AAN = American Academy of Neurology
AIMS = Abnormal Involuntary Movement Scale
FDA = US Food and Drug Administration
GABA = gamma-aminobutyric acid
TD = tardive dyskinesia
VMAT2 = vesicular monoamine transporter 2

© Copyright 2019 Physicians Postgraduate Press, Inc.

References

  1. Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371–1380. PubMed CrossRef
  2. Carbon M, Hsieh C-H, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278. PubMed CrossRef
  3. Othman Z, Ghazali M. Asrenee AR, et al. Severity of tardive dyskinesia and negative symptoms are associated with poor quality of life in schizophrenia patients. Int Med J. 2013;20(6):677–680.
  4. Infographic: 5 steps for taking on tardive dyskinesia. Mental Health America. https://www.mhanational.org/infographic-5-steps-taking-tardive-dyskinesia. Published November 9, 2017. Accessed July 26, 2018.
  5. Pakpoor J, Agius M. A review of the adverse side effects associated with antipsychotics as related to their efficacy. Psychiatr Danub. 2014;26(suppl 1):273–284. PubMed
  6. Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–148, viii. PubMed CrossRef
  7. Bhidayasiri R, Fahn S, Weiner WJ, et al; American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–469. PubMed CrossRef
  8. Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75. PubMed CrossRef
  9. Caroff SN, Mu F, Ayyagari R, et al. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 2018;18(1):306. PubMed CrossRef
  10. Cornett EM, Novitch M, Kaye AD, et al. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–174. PubMed
  11. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–176. PubMed CrossRef
  12. Xenazine (tetrabenazine) [package insert]. Washington, DC: Prestwick Pharmaceuticals, Inc; May 2008.
  13. Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat. 2010;6:657–665. PubMed CrossRef
  14. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011;45(4):525–531. PubMed CrossRef
  15. Pharmacotherapy Update Ginkgo Biloba and Memory.
    https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/sepoct02/ginkgo.htm. Accessed June 18, 2019.
  16. Staff E. Klonopin addiction treatment (clonazepam). American Addiction Centers. https://americanaddictioncenters.org/klonopin-treatment. Accessed June 18, 2019.
  17. Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018;18(4):323–332. PubMed CrossRef
  18. Citrome L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71(7). PubMed
  19. Citrome L. Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71(11):e13030. PubMed CrossRef
  20. Ingrezza (valbenazine): Highlights of prescribing information. July 2019. https://ingrezza.com/PI. Accessed July 29, 2019.
  21. Austedo (deutetrabenazine): Highlights of prescribing information. July 2019. https://www.austedo.com/globalassets/austedo/prescribing-information.pdf. Accessed July 29, 2019.
  22. Niemann N, Jankovic J. Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018;78(5):525–541. PubMed CrossRef
  23. Factor S, Hauser R, Mandri D, et al. A phase 2 study of valbenazine (nbi-98854) for treatment of tardive dyskinesia: KINECT 2 (s27.007). Neurology. 2016;86(16 suppl):S27.007.
  24. Stacy M, Sajatovic M, Kane JM, et al. Abnormal involuntary movement scale in tardive dyskinesia: minimal clinically important difference. Mov Disord. 2019;34(8):1203–1209. PubMed CrossRef
  25. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–484. PubMed CrossRef
  26. Thai-Cuarto D, O’Brien CF, Jimenez R, et al. Cardiovascular profile of valbenazine: analysis of pooled data from three randomized, double-blind, placebo-controlled trials. Drug Saf. 2018;41(4):429–440. PubMed CrossRef
  27. Marder SR, Sajatovic M, Michel D, et al. Long-term safety and tolerability of once-daily valbenazine in patients with tardive dyskinesia. CNS Spectr. 2019;24(1):196. PubMed CrossRef
  28. Lindenmayer J-P, Marder SR, Singer C, et al. Long-term valbenazine treatment in patients with schizophrenia/schizoaffective disorder or mood disorder and tardive dyskinesia. CNS Spectr. 2019;24(1):214–215. PubMed CrossRef
  29. Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017;78(9):1344–1350. PubMed CrossRef
  30. Touma KTB, Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci. 2018;15(5–6):13–16. PubMed
  31. A Kinetic Kick-Start: Deutetrabenazine (AustedoTM)- the First FDA Approved Deuterated Drug. Scientific Update UK. https://www.scientificupdate.com/process-chemistry-articles/a-kinetic-kick-start-deutetrabenazine-austedotm-the-first-fda-approved-deuterated-drug/. Accessed June 20, 2019.
  32. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003–2010. PubMed CrossRef
  33. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604. PubMed CrossRef
  34. Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia [published online ahead of print July 10, 2019]. J Neurol Neurosurg Psychiatry. PubMed CrossRef

Volume: 81

Quick Links:

References

RECENT ARTICLES
CASE REPORT
Kevin Chen and others

INFORMATION FROM INDUSTRY
NARRATIVE REVIEW
Amber N. Khan and others

CASE REPORT
Tanvi Mittal and others

COMMENTARY
Anshul V. Puli and others